For example, a recent study demonstrated that T cells engineered with TCRs of the ten most abundant CD8+PD-1+ clonotypes from a TIL had reactivity against cancer germline antigens and neoantigens (Pasetto et al., 2016). This evidence concerns the gene CD8A and cancer.